Major Depressive Disorder Clinical Trial
Official title:
The Study of Mindfulness-based Cognitive Therapy and Major Depressive Disorder
The primary objective of the study is to evaluate the clinical curative effect of
mindfulness-based cognitive therapy(MBCT) for major depressive disorder(MDD). Moreover, we
will also explore the relationship between P300 potential and erroneous negative potential
(ERN) variation and clinical symptoms in MDD and MBCT.
This study is a randomized-control trial with two study arms: half of patient cases will
receive usual medication treatment with the serotonin reuptake inhibitors (SSRIs) and half of
patient cases will receive MBCT added to the usual medication treatment. This study is also a
case-control trial, there will be matched normal controls compared with patient cases through
a range of psychological scales and electroencephalogram.
The study is designed as a prospective, assessor-blinded, randomized-control, case-control
clinical trial with 70 MDD cases and 35 matched normal controls.After signed the Informed
consents, MDD cases will be assigned to two groups randomly by the table generated by
Microsoft Excel 2010 to ensure the random distribution between groups. The group of each
patient will be allotted by the research coordinator so that evaluators will be blind about
it, and patients will be asked to not mention the intervention conditions to evaluators.
As the research tools, a range of self-rating scales, other-rating scales and behavioral
tests and EEG will be mainly applied to assess clinical symptoms and brain state of
participants at baseline (week 0), during the intervention (week 2, 4 and 6), at the end of
the intervention (week 8), and during the maintenance phase (week 12, 20 and 32).
After 8-week intervention, all of the participants including MDD cases and normal controls
will enter the follow-up. Participants of medication group will continue their treatment
options without changing the types and doses of medication compared with what they used in
the intervention period. MBCT group is the same that participants will maintain their
medication treatment and practice MBCT exercises at home.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |